more_reports

The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports

Study Shows 93% Cough Suppression With Co.'s Drug

  ()
Clinical-stage pharmaceutical development company Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGN0:XFRA) announced the drug ifenprodil achieved a 93% reduction in median cough count in an acute guinea pig citric acid challenge study. Find out why one analyst says this stock is headed for a "major bull market."

Could This Stock Be the Next Bellus Cough Treatment?

Contributed Opinion
  ()
Technical Analyst Clive Maund shares an extensive overview of Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGN0:XFRA) to explain why he believes it is a Strong Buy.

LA Biotech Unveils New Patented Nicotinamide Riboside Chloride

Research Report
  ()
"The advent of NIAGEN IV could usher in a powerful new tailwind for revenue growth at ChromaDex Corp. (CDXC:NASDAQ)," noted an H.C. Wainwright & Co. report.

Biopharma Co. Reports Strong FQ224 Results Driven

Research Report
  ()
Leede Financial Inc. analyst Dr. Douglas W. Loe wrote he is maintaining his target price and Buy rating on Theratechnologies Inc. (TH:TSX).

Texas Biotech Announces Plans for Preclinical Obesity Studies

Research Report
  ()
Bio-Path Holdings Inc. (BPTH:NASDAQ) recently announced its progress in its cancer clinical trials and plans to begin preclinical obesity studies, according to a Roth MKM research note.

AI Health Stock Heading Higher Expert Says

Contributed Opinion
  ()
Technical Analyst Clive Maund gives an update on Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) as he believes "something is going on" and the stock may be heading higher.

California Biotech Reports Positive Phase 3 Results

Research Report
  ()
"Along with the significantly lower pill burden compared to other phosphate binders, we believe the superior tolerability may be attributable to OLC's nanoparticle technology," noted an H.C. Wainwright & Co. research note, regarding Unicycive Therapeutics Inc.'s (UNCY:NASDAQ) trial of oxylanthanum carbonate (OLC) for the treatment of hyperphosphatemia in chronic kidney disease (CKD) patients.

Clean Tech Subsidiary Finds Manufacturer for Wound Solution

  ()
BioLargo Inc. (BLGO:OTCQB) announced that subsidiary Clyra Medical Technologies Inc. has selected a company to support the manufacturing of its medical products, including its surgical wound irrigation solution, Bioclynse. See why one nonprofit group says the rate of healthcare-associated infections has remained high since the pandemic.

Is This Pharma Co. the Next Eli Lilly?

  ()
Nervgen Pharma Corp. (NGEN:TSX.V; NGENF:OTCQX) is making significant strides in the field of nerve damage and spinal cord injury treatments. Find out about the company's future plans and why Chen Lin of What is Chen Buying? What is Chen Selling? said he believes Nervgen could potentially become the next Eli Lilly.

Rare Disease Co. Presents Positive Phase 2 KP1077 Data

Research Report
  ()
Zevra Therapeutics Inc. (ZVRA:NASDAQ) recently presented positive final results from its Phase 2 trial evaluating KP1077 in idiopathic hypersomnia (IH) patients at the SLEEP 2024 conference, according to a Roth MKM research note.

Pharma Co. Secures $650M Strategic Financing

Research Report
  ()
According to a Canaccord Genuity research note, Verona Pharma Plc. received a US$650 million strategic financing, which management believes will extend the cash runway beyond 2026 and fund the upcoming commercial activities related to the potential FDA approval of ensifentrine.

New COPD Drug Slated for Approval Decision This June

  ()
Ahead of the upcoming PDUFA date, several analysts recommend the biopharma behind this treatment as a Buy. Read on to learn why.

Pharma Stock Focuses on Successful Ensifentrine Launch

Research Report
  ()
Verona Pharma Plc. is well positioned to launch its ensifentrine into the substantial market of nearly 9 million COPD patients, according to a BTIG Research note.

Pharma Stock Nears FDA Approval

Research Report
  ()
According to a Jefferies & Co. research note, Verona Pharma Plc. is at the final stretch for its FDA approval.

Breakthrough COPD Treatment Awaits FDA Approval, Promising Major Market Impact

  ()
Verona Pharma is poised for a pivotal breakthrough with its drug candidate, ensifentrine, potentially transforming COPD treatment pending an upcoming FDA decision. Read on for more.

Biotech Co. Positioned for Ensifentrine Approval, Analyst Says

Research Report
  ()
According to a Jefferies & Co. research note, Verona Pharma Plc. has a 90-95% probability of success for PDUFA approval.

Pharma's Promising Path in COPD Treatment

  ()
As Verona Pharma releases more news surrounding its COPD treatments, analysts are taking notice. Read to see what Verona is doing in the pharmaceutical space and what three analysts have to say about this company's stock.

Biopharma's New Drug for COPD Likely to be Approved

Research Report
  ()
Characteristics of the Buy-rated company's lead candidate make it "an intriguing commercial prospect," noted an H.C. Wainwright & Co. report.

PDUFA Date Coming Up for U.K. Biopharma

Research Report
  ()
The company has a commercialization plan in place and is preparing further for approval, noted a Canaccord Genuity report.

Analyst Says Pharma Co. Has No True Competitor

Research Report
  ()
Verona Pharma Plc. recently is gearing up for a potential FDA approval of its twice-daily ensifentrine, according to a Jefferies & Co. research note.

LA Biotech's Lower Revenue Will Be Short Lived

Research Report
  ()
While Ontrak Inc. may have had a loss in revenue in 2023, this will be short-lived, according to a Roth MKM research note.

Chen in Q2 2024: It's Silver, Again, as Precious Metal Breaks Out

  ()
After being bullish on silver for at least the last year, asset manager Chen Lin feels a little vindicated by the precious metal's recent two-year high.

Biotech's Lawsuit With Eli Lilly Might Catalyze Stock

  ()
Nektar Therapeutics has commenced a Phase 2b clinical trial evaluating its lead product candidate rezpegaldesleukin in patients with severe to very severe alopecia areata. In other news, Nektar has a lawsuit pending against Eli Lilly & Co. Read on to see what two experts have to say about this biotech stock.

Biotech Stocks Break Out

Contributed Opinion
  ()
Ron Struthers of Struthers Stock Report shares that the S&P Biotech SPDR is over 60% this year and trading around $100 a share. He also details how well he has down, buying under valued cash-rich biotechs in 2023, and shares one stock he believes it worth looking into.

Biotech Co.'s Target Price Significantly Higher Than Current

Research Report
  ()
Biofrontera Inc. is currently trading at US$1.26, but has a target price of US$26, according to a Roth MKM research note.

Showing Results: 1 to 25 of 34 Next